United Kingdom (UK)
Recombinant monoclonal antibody to E protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the human B cell clone T025.
UniProt Accession Number of Target Protein: P14336
Alternative Name(s) of Target: tick-borne encephalitis virus; TBEV; envelope domain III; EDIII; envelope protein
Specificity: This antibody binds a conserved epitope near the lateral ridge of EDIII adjoining the EDI–EDIII hinge region of the E protein (EDIII) of TBEV. The antibody recognises three subtypes of TBEV EDIII: Western European (TBEVWE), Far Eastern (TBEVFE), and Siberian (TBEVSi). The antibody cross reacts with other tick-borne flaviviruses, including Langat, louping ill, Omsk hemorrhagic fever and Kyasanur forest disease.
Application Notes: The specificity of the original format of the antibody was confirmed by ELISA analysis. The antibody showed neutralizing activity against TBEV RVPs authentic TBEV (IC50= 67 ng/ml). Immunofluorescence was performed on PS cells using this antibody. Prophylaxis experiments in BALB/c mice infected with TBEV showed the antibody was efficacious in prevention and early treatment of the infection. The crystal structure of the Fab fragment in complex with the EDIII domains was determined (Agudelo et al. 2021; PMID: 33831141).
Antibody first published in:
Agudelo et al. Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. J Exp Med. 2021 May 3; 218(5): e20210236. PMID:33831141
Note on publication:
The paper describes the generation and characterization of a panel of antibodies specific for TBEV.